Skip to main content
Clinical Trials/NCT03287193
NCT03287193
Recruiting
N/A

Identification of the Molecular and/or Pathophysiological Bases of Rare Diseases of Genetic Origin (or Rare Forms of Frequent Diseases Suspected of Being of Genetic Origin).

Centre Hospitalier Universitaire Dijon1 site in 1 country850 target enrollmentMarch 13, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Centre Hospitalier Universitaire Dijon
Enrollment
850
Locations
1
Primary Endpoint
Number of new genes or genetic abnormalities identified.
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

Rare diseases are conditions affecting a small number of people, requiring specific and often multidisciplinary medical care. There are over 7,000 rare diseases, around 80% of which are genetic in origin. These diseases are generally severe, chronic and progressive, and can considerably affect the quality of life of sufferers.

Although significant efforts in the search for genetic causes over the last two decades have led to the identification of thousands of genes associated with Mendelian diseases, half of all individuals with a rare disease remain without a genetic diagnosis. It is important to pursue the ambition of participating in the effort set by Europe, namely the identification of a large majority of the genetic causes responsible for rare diseases, and to be able to provide genetic counselling to patients and their families. In the past, scientific research to discover genes required a large number of families and individuals, and was long and costly to carry out. Today, this approach is facilitated by next-generation sequencing.

When high-throughput sequencing (HTS) identifies candidate genes or genetic abnormalities, it may be necessary to propose functional analyses to try to reach a conclusion.

Registry
clinicaltrials.gov
Start Date
March 13, 2017
End Date
December 1, 2027
Last Updated
4 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients (children or adults) with a suspected rare disease (or rare form of a common disease) of genetic origin for which the molecular basis is not known, or for which the understanding of the physiopathological mechanism is imperfectly known.
  • Foetuses with developmental abnormalities for which the molecular basis is not known, or for which the understanding of the physiopathological mechanism is imperfectly known.
  • Apparently healthy relatives or controls AND
  • Consent of the patient or his/her legal representative
  • Suitable level of understanding

Exclusion Criteria

  • Patients without national health insurance cover

Outcomes

Primary Outcomes

Number of new genes or genetic abnormalities identified.

Time Frame: through study completion, an average of 5 years

Study Sites (1)

Loading locations...

Similar Trials